Search results for "Cytochrome P-450 CYP2C9"

showing 6 items of 6 documents

Upgrading cytochrome P450 activity in HepG2 cells co-transfected with adenoviral vectors for drug hepatotoxicity assessment

2011

In a number of adverse drug reactions leading to hepatotoxicity, drug metabolism is thought to be involved by the generation of reactive metabolites from non-toxic drugs. The use of hepatoma cell lines, such as HepG2 cell line, for the evaluation of drug-induced hepatotoxicity is hampered by their low cytochrome P450 expression which makes impossible the study of the toxicity produced by bioactivable compounds. Genetically manipulated cells constitute promising tools for hepatotoxicity applications. HepG2 cells were simultaneously transfected with recombinant adenoviruses encoding CYP1A2, CYP2C9 and CYP3A4 to confer them drug-metabolic competence. Upgraded cells (Adv-HepG2) were highly able…

Aflatoxin B1Cell SurvivalGenetic VectorsPharmacologyTransfectionToxicologyModels BiologicalCitric AcidCalcium in biologyAdenoviridaeCytochrome P-450 CYP1A2RotenoneCytochrome P-450 CYP3AHumansViability assayCytochrome P-450 CYP2C9Membrane Potential MitochondrialCYP3A4biologyChemistryCYP1A2Cytochrome P450Hep G2 CellsGeneral MedicineTransfectionBiochemistryHigh-content screeningbiology.proteinCalciumAryl Hydrocarbon HydroxylasesChemical and Drug Induced Liver InjuryDrug metabolismToxicology in Vitro
researchProduct

Role of genetic factors on the effect of additional loading doses and two maintenance doses used to overcome clopidogrel hyporesponsiveness.

2014

Background and objective: Additional loading doses and higher maintenance doses (MDs) have been used to overcome hyporesponsiveness of clopidogrel. We aimed to investigate whether genetic polymorphisms of two cytochromes (CYP2C19 and CYP2C9) and ABCB1 modify effect of such dose-adjustment strategy.Materials and methods: We enrolled 118 patients undergoing elective or acute percutaneous coronary intervention (PCI) with drug eluting stent (DES). Platelet reactivity index (PRI) was measured using the vasodilator-stimulated phosphoprotein (VASP) index and a cut-off value of ≥60% was defined as hyporesponsiveness. Polymorphism of two cytochromes (CYP2C19, CYP2C9) and gene ABCB1 were determined. …

CYP2C9MaleMedicine (General)ATP Binding Cassette Transporter Subfamily BTiclopidinemedicine.medical_treatmentCYP2C19PharmacologyR5-920Percutaneous Coronary InterventionmedicinePotencyHumansProspective StudiesCYP2C19AlleleCYP2C9AllelesAgedCytochrome P-450 CYP2C9Medicine(all)Polymorphism GeneticDose-Response Relationship Drugbusiness.industryClopidogrel resistanceMicrofilament ProteinsPercutaneous coronary interventionABCB1Drug-Eluting StentsVASPMiddle AgedClopidogrelPhosphoproteinsClopidogrelCytochrome P-450 CYP2C19Drug-eluting stentPharmacogeneticsAutomotive EngineeringConventional PCIFemalebusinessCell Adhesion MoleculesPlatelet Aggregation InhibitorsClopidogrel resistance; VASP; CYP2C19; ABCB1; CYP2C9medicine.drugMedicina (Kaunas, Lithuania)
researchProduct

Re-expression of C/EBP alpha induces CYP2B6, CYP2C9 and CYP2D6 genes in HepG2 cells.

1998

Cytochrome P450 (CYP) activity is very low or even absent in human hepatomas, a phenomenon that is accompanied by low levels of some liver transcription factors, notably C/EBP alpha. To investigate a possible link between this transcription factor and hepatic CYP expression, we have stably transfected HepG2 cells with a C/EBP alpha vector containing a Zn-inducible metallothionein promoter. Expression of functional C/EBP alpha up to liver levels concomitantly increased the mRNAs of several members of the CYP2 family (2B6, 2C9 and 2D6), suggesting that this transcription factor may play a relevant role in controlling the hepatic expression of CYP enzymes.

Carcinoma HepatocellularCYP2B6BiophysicsHepG2 cellTransfectionBiochemistryGene Expression Regulation EnzymologicCytochrome P-450 Enzyme SystemStructural BiologyTumor Cells CulturedGeneticsHumansMetallothioneinRNA MessengerVector (molecular biology)Molecular BiologyTranscription factorGeneCells CulturedCytochrome P-450 CYP2C9biologyChemistryNuclear ProteinsCytochrome P450Oxidoreductases N-DemethylatingCell BiologyTransfectionMolecular biologyDNA-Binding ProteinsCytochrome P-450 CYP2B6C/EBPαCytochrome P-450 CYP2D6Steroid 16-alpha-HydroxylaseHepatocyte nuclear factor 4 alphaEnzyme InductionSteroid HydroxylasesCCAAT-Enhancer-Binding Proteinsbiology.proteinAryl Hydrocarbon HydroxylasesHuman hepatocyteCytochrome P450 gene regulationTranscription Factors
researchProduct

Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways.

1999

The aim of this study was to re-examine the human hepatic metabolism of diclofenac, with special focus on the generation of minor hydroxylated metabolites implicated in the idiosyncratic hepatotoxicity of the drug. Different experimental approaches were used: human hepatocytes, human microsomes, and engineered cells expressing single human CYP (cytochromes P450). Human hepatocytes formed 3'-hydroxy-, 4'-hydroxy-, 5-hydroxy- 4',5-dihydroxy-, and N,5-dihydroxydiclofenac, as well as several lactams. Formation of 4'- and 5-hydroxydiclofenac by human liver microsomes followed a Michaelis-Menten kinetics (Km 9 +/- 1 microM; Vmax 432 +/- 15 pmol/min/mg and Km 43 +/- 5 microM; and Vmax 15.4 +/- 0.6…

DiclofenacMetaboliteIn Vitro TechniquesBiochemistryCell LineHydroxylationCytochrome P-450 CYP2C8chemistry.chemical_compoundTolbutamideCytochrome P-450 Enzyme SystemmedicineHumansBiotransformationCytochrome P-450 CYP2C9PharmacologybiologyAnti-Inflammatory Agents Non-SteroidalCytochrome P450Metabolismmedicine.anatomical_structureBiochemistrychemistrySteroid 16-alpha-HydroxylaseHepatocyteSteroid HydroxylasesMicrosomebiology.proteinMicrosomes LiverAryl Hydrocarbon HydroxylasesOxidation-ReductionDrug metabolismmedicine.drug
researchProduct

Transcriptional activation of CYP2C9, CYP1A1, and CYP1A2 by hepatocyte nuclear factor 4alpha requires coactivators peroxisomal proliferator activated…

2006

Hepatocyte nuclear factor 4alpha (HNF4alpha) is a key transcription factor for the constitutive expression of cytochromes P450 (P450s) in the liver. However, human hepatoma HepG2 cells show a high level of HNF4alpha but express only marginal P450 levels. We found that the HNF4alpha-mediated P450 transcription in HepG2 is impaired by the low level of coactivators peroxisomal proliferator activated receptor-gamma coactivator 1alpha (PGC1alpha) and steroid receptor coactivator 1 (SRC1). Reporter assays with a chimeric CYP2C9-LUC construct demonstrated that the sole transfection of coactivators induced luciferase activity in HepG2 cells. In HeLa cells however, CYP2C9-LUC activity only significa…

MaleTranscriptional Activationendocrine systemBiologyResponse ElementsTransfectiondigestive systemAdenoviridaeNuclear Receptor Coactivator 1Cytochrome P-450 CYP1A2CoactivatorCytochrome P-450 CYP1A1HumansInsulinTranscription factorCells CulturedHeat-Shock ProteinsCytochrome P-450 CYP2C9Histone AcetyltransferasesPharmacologyTransfectionMiddle AgedMolecular biologyPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaNuclear receptor coactivator 1Hepatocyte nuclear factorsHepatocyte Nuclear Factor 4Nuclear receptor coactivator 3Nuclear receptor coactivator 2HepatocytesMolecular MedicineFemaleAryl Hydrocarbon HydroxylasesChromatin immunoprecipitationHeLa CellsProtein BindingTranscription FactorsMolecular pharmacology
researchProduct

Genotype-driven pharmacokinetic simulations of warfarin levels in Puerto Ricans.

2020

Abstract Objectives The inter-individual variability of warfarin dosing has been linked to genetic polymorphisms. This study was aimed at performing genotype-driven pharmacokinetic (PK) simulations to predict warfarin levels in Puerto Ricans. Methods Analysis of each individual dataset was performed by one-compartmental modeling using WinNonlin®v6.4. The k e of warfarin given a cytochrome P450 2C9 (CYP2C9) genotype ranged from 0.0189 to 0.0075 h−1. K a and V d parameters were taken from literature. Data from 128 subjects were divided into two groups (i.e., wild-types and carriers) and statistical analyses of PK parameters were performed by unpaired t-tests. Results In the carrier group (n=6…

medicine.medical_specialtyGenotypeCmax030204 cardiovascular system & hematology030226 pharmacology & pharmacyGastroenterologyArticle03 medical and health sciences0302 clinical medicinePharmacokineticsVitamin K Epoxide ReductasesInternal medicineGenotypemedicineHumansPharmacology (medical)DosingGeneral Pharmacology Toxicology and PharmaceuticsCYP2C9GenotypingCytochrome P-450 CYP2C9business.industryWarfarinArea under the curveFarmàcia InvestigacióAnticoagulantsHispanic or LatinoAryl Hydrocarbon HydroxylasesWarfarinbusinessmedicine.drugDrug metabolism and personalized therapy
researchProduct